Mavyret, Maviret(glecaprevir)
Maviret, Mavyret (glecaprevir) is a small molecule pharmaceutical. Glecaprevir was first approved as Maviret on 2017-07-26. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Mavyret
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mavyret | New Drug Application | 2023-10-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatitis c | — | D006526 | B19.2 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
GLECAPREVIR / PIBRENTASVIR, MAVYRET, ABBVIE | |||
| 2028-12-10 | PED | ||
| 2028-06-10 | ODE-372 | ||
| 2026-10-30 | PED | ||
| 2026-04-30 | ODE-232, ODE-233 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Glecaprevir / Pibrentasvir, Mavyret, Abbvie | |||
| 11246866 | 2036-06-24 | DP | |
| 9321807 | 2035-06-05 | DP | |
| RE48923 | 2035-05-08 | DP | |
| 10286029 | 2034-03-14 | U-3237, U-3238 | |
| 11484534 | 2034-03-14 | U-3237 | |
| 8937150 | 2032-05-18 | DS, DP | |
| 8648037 | 2032-01-19 | DS, DP | U-2141, U-3237, U-3238 |
| 9586978 | 2030-11-06 | U-2141, U-3237, U-3238 | |
| 10028937 | 2030-06-10 | U-2141, U-3237, U-3238 | |
| 10039754 | 2030-06-10 | U-2141, U-3237, U-3238 | |
HCPCS
No data
Clinical
Clinical Trials
72 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | — | 7 | 25 | 3 | 11 | 42 |
| Hepatitis | D006505 | — | K75.9 | — | 7 | 25 | 3 | 9 | 40 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 7 | 24 | 2 | 9 | 38 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | 1 | — | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 5 | 19 | — | 7 | 28 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 5 | 18 | — | 6 | 26 |
| Hepacivirus | D016174 | — | — | — | 4 | 8 | — | — | 10 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 8 | — | — | 9 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 4 | — | 1 | 6 |
| Fibrosis | D005355 | — | — | — | 1 | 4 | — | 1 | 6 |
| Communicable diseases | D003141 | — | — | — | 1 | 4 | — | — | 5 |
| Virus diseases | D014777 | — | B34 | — | 1 | 4 | — | — | 5 |
| Hepatitis b | D006509 | — | — | — | — | 3 | — | 2 | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 3 | — | — | 4 |
Show 3 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Glecaprevir |
| INN | glecaprevir |
| Description | Glecaprevir (INN,) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.
|
| Classification | Small molecule |
| Drug class | antivirals: serine protease inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)[C@@H]1NC(=O)O[C@@H]2CCC[C@H]2OC/C=C/C(F)(F)c2nc3ccccc3nc2O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3C(F)F)N(C2)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 1365970-03-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545363 |
| ChEBI ID | — |
| PubChem CID | 66828839 |
| DrugBank | DB13879 |
| UNII ID | K6BUU8J72P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Mavyret – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,031 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mavyret
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,366 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use